REGENERON COMPLETES ENROLLMENT IN INFLAMMATORY DISEASE TRIAL

A A

Regeneron Pharmaceuticals has completed enrollment for a pivotal trial in its Phase III program for the treatment of CIAS1-associated periodic syndrome, or CAPS, a spectrum of very rare genetic autoinflammatory disorders.

The trial will include a six-month, placebo-controlled efficacy phase and be followed by a six-month, open label extension phase, which will help to characterize the safety of the IL-1 trap. The efficacy phase of this trial is expected to be completed by the end of 2006.